Jayne D R, Lockwood C M
Division of Renal Medicine, St George's Hospital Medical School, University of London.
Br J Rheumatol. 1996 Nov;35(11):1150-3. doi: 10.1093/rheumatology/35.11.1150.
High-dose, pooled, i.v. immunoglobulin (IVIg) is a potential, alternative treatment for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) which has shown promise in the treatment of refractory disease when administered with continuing immunosuppression. This study of six new patients with antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis and early disease, without threatened vital organ function, examined the therapeutic response to treatment with IVIg alone. IVIg was well tolerated and all six patients had early reductions in disease activity. Four entered full, clinical remission which lasted for at least 1 yr, while in two the responses were partial and transient, and they subsequently required conventional treatment. After 16-48 months of follow-up, two of the four patients in full remission relapsed, but the other two have remained well.
大剂量静脉注射用人免疫球蛋白(IVIg)是韦格纳肉芽肿(WG)和显微镜下多血管炎(MPA)的一种潜在替代治疗方法,在与持续免疫抑制联合使用时,已显示出对难治性疾病的治疗前景。这项针对6例抗中性粒细胞胞浆抗体(ANCA)阳性血管炎且疾病早期、重要器官功能未受威胁的新患者的研究,考察了单独使用IVIg治疗的疗效。IVIg耐受性良好,所有6例患者的疾病活动度在早期均有所降低。4例实现完全临床缓解,持续至少1年,而另外2例的缓解是部分性且短暂的,随后需要接受常规治疗。随访16 - 48个月后,4例完全缓解患者中有2例复发,但另外2例仍情况良好。